Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 11.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,586 shares of the company’s stock after purchasing an additional 1,318 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Twist Bioscience were worth $585,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Massachusetts Financial Services Co. MA grew its holdings in Twist Bioscience by 215.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after acquiring an additional 20,035 shares during the period. Barclays PLC increased its holdings in shares of Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after purchasing an additional 104,420 shares in the last quarter. FMR LLC increased its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Twist Bioscience in the fourth quarter valued at about $1,059,000. Finally, BNP Paribas Financial Markets boosted its holdings in Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after buying an additional 21,357 shares in the last quarter.

Insiders Place Their Bets

In related news, COO Patrick John Finn sold 10,340 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the completion of the transaction, the chief operating officer now owns 221,061 shares of the company’s stock, valued at approximately $10,610,928. This represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the transaction, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. This trade represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 80,407 shares of company stock valued at $3,757,443 in the last quarter. 3.01% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on TWST. Barclays reduced their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, November 19th. Scotiabank upped their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $52.37 on Monday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a 50 day simple moving average of $48.39 and a 200-day simple moving average of $46.23. The firm has a market cap of $3.11 billion, a PE ratio of -14.55 and a beta of 1.85.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.